

I vaccini anti-SARS-CoV2 in sperimentazione di fase 3

descrizione della piattaforma	tipo di vaccino candidato	trials	sviluppatori
virus inattivato	Vaccino inattivato SARS-CoV-2 (Vero cell)	ChiCTR2000034780 ChiCTR2000039000 NCT04510207 NCT04612972	Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products
virus inattivato	Vaccino inattivato SARS-CoV-2 (Vero cell)	NCT04560881 NCT04510207	Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products
vettore virale non replicante	Nuovo vaccino ricombinante contro il coronavirus (Adenovirus type 5 vector)	NCT04526990 NCT04540419	CanSino Biological Inc./Beijing Institute of Biotechnology
vettore virale non replicante	Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S)	NCT04530396 NCT04564716 NCT04642339 NCT04656613	Gamaleya Research Institute ; Health Ministry of the Russian Federation
vettore virale non replicante	Ad26.COV2.S	NCT04505722 NCT04614948	Janssen Pharmaceutical
subunità proteica	SARS-CoV-2 rS/Matrix M1-Adjuvant (vaccino con nanoparticelle di glicoproteina SARS CoV-2 ricombinante adiuvato con Matrix M)	NCT04611802 EUCTR2020-004123-16-GB NCT04583995	Novavax
subunità proteica	Vaccino SARS-CoV-2 ricombinante (CHO Cell)	NCT04646590	Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences
vaccino a RNA	CVnCoV Vaccine	NCT04674189	CureVac AG
virus inattivato	SARS-CoV-2 vaccine (vero cells)	NCT04659239	Institute of Medical Biology + Chinese Academy of Medical Sciences
virus inattivato	QazCovid-in® - vaccino inattivato COVID-19	NCT04691908	Research Institute for Biological Safety Problems, Rep of Kazakhstan
vaccino a DNA	nCov vaccine	CTRI/2020/07/026352	Cadila Healthcare Ltd.
virus inattivato	Vaccino SARS-CoV-2 inattivato a virione intero (BBV152)	NCT04641481	Bharat Biotech International Limited